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Abstract
A strategy is described for the re-design of DNA damaging platinum(II) complexes to afford elevated
toxicity towards cancer cells expressing the estrogen receptor (ER). Two platinum-based toxicants
are described in which a DNA damaging warhead, [Pt(en)Cl2] (en, ethylenediamine), is tethered to
either of two functional groups. The first agent, [6-(2-amino-ethylamino)-hexyl]-carbamic acid 2-
[6-(7α-estra-1,3,5,(10)-triene)-hexylamino]-ethyl ester platinum(II) dichloride ((Est-en)PtCl2),
terminates in a ligand for the ER. The second agent is a control compound lacking the steroid; this
compound, N-[6-(2-amino-ethylamino)-hexyl]-benzamide platinum(II) dichloride ((Bz-en)PtCl2)),
terminates in a benzamide moiety, which lacks affinity for the ER. Using a competitive binding assay,
Est-en had 28% relative binding affinity (RBA) for the ER as compared to 17β-estradiol. After
covalent binding to a synthetic DNA duplex 16-mer, the compound retained its affinity for the ER;
specificity of the binding event was demonstrated by the ability of free 17β-estradiol as a competitor
to disrupt the DNA adduct-ER complex. The (Est-en)PtCl2 compound showed higher toxicity against
the ER positive ovarian cancer cell line CAOV3 than did the control compound. (Est-en)PtCl2 was
also more toxic to the ER positive breast cancer line, MCF7, than to an ER negative line, MDA-
MB231.
1. Introduction
Platinum compounds such as cisplatin, carboplatin and oxaliplatin are successful anticancer
agents [1]. The former two agents are particularly effective in the treatment of testicular
cancers, for which cure rates exceed 90% [2,3], whereas the third agent is used in treatment of
colorectal cancer [4]. Platinum compounds are also used for treatment of other cancers,
including those of the ovary, head and neck, and cervix [5]. However, as with most cancer
therapeutics, clinical use of platinum antitumor agents is frequently limited by unwanted toxic
side effects and acquired and/or intrinsic resistance against the drugs [1,6]. Efforts toward the
development of next-generation platinum anticancer agents have been aimed at overcoming
the aforementioned limitations.
The major mechanism of action of platinum compounds is through their ability to bind
covalently to DNA [7]. Once DNA adducts are formed, cellular survival depends on the DNA-
repair capabilities of the cells. Some cisplatin-resistant cell lines derived from tumors have
increased rates of repair compared to cells from clinically responsive tumors [8]. Increased
expression of the nucleotide excision repair (NER) endonuclease ERCC1 has been correlated
with cisplatin resistance in ovarian cancer [9]. Cisplatin DNA-adducts also serve as recognition
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motifs for a variety of cellular proteins that are not involved in DNA repair [10]. Binding of
these proteins also plays a role in modulating the cytotoxic effects of platinum compounds
[11]. The relevance of these mechanisms to clinical responses is under continued investigation.
Nevertheless, the discovery of proteins that bind tightly to platinum adducts provided the basis
for a concept for the rational design of compounds that overcome resistance mechanisms and
sensitize tumor cells to platinum compounds and other cytotoxic drugs.
Earlier work from our laboratory [12,13] resulted in the synthesis of compounds in which DNA-
interactive nitrogen mustards were tethered to ligands for steroid receptors (either the androgen
or the estrogen receptors). Some of these compounds have shown preferential toxicity against
the relevant steroid receptor positive cells in culture and significant promise against animal
xenograft models of human cancer. The objective of the current study was to explore the
feasibility of using a steroid ligand, a derivative of estradiol, as a targeting agent that would
enhance the toxicity of platinating agents in cells.
The compounds prepared in this work, and their intended mechanisms of action, are shown in
Figure 1. The control compound, N-[6-(2-amino-ethylamino)-hexyl]-benzamide ((Bz-en)
PtCl2) (Fig. 1A) readily forms DNA adducts (vide infra) but does not interact with the ER
owing to the absence of functional ligand. We propose that this compound forms adducts that
can be readily repaired by the host cell nucleotide repair system. The compound may affect
transcription but such effects would be assumed to be non-specific. By contrast, [6-(2-amino-
ethylamino)-hexyl]-carbamic acid 2-[6-(7α-estra-1,3,5,(10)-triene)-hexylamino]-ethyl ester
((Est-en)PtCl2) was designed to form adducts that interact with the ER (Fig. 1B). If such
interactions occur in cells, the ER-adduct complex may camouflage the lesion from DNA repair
systems that have the genome under surveillance in order to correct endogenously and
exogenously generated genetic damage. If unrepaired, the adduct would possibly trigger a
lethal event. As a second possible mechanism, the adducts of (Est-en)PtCl2, if sufficiently
abundant in the genome, could hijack a sufficient amount of the ER to prevent this transcription
factor from performing its growth enhancing function in ER positive cancer cells. The third
possibility is that the ER may form a complex with the free (Est-en)PtCl2 compound and help
deliver it to DNA. Before these models could be tested, it was necessary to synthesize a
platinum warhead that could form DNA adducts capable of interacting with the ER in a
biologically relevant manner. That issue is the subject of this initial paper.
2. Experimental
2.1 General Methods
All reagents and solvents were purchased from commercial sources and were of reagent quality
unless otherwise stated. Moisture-sensitive reactions were handled under argon atmosphere
using standard Schlenk techniques. Solvents used for synthesis were glass-distilled anhydrous
or of the highest quality available, and were used without further purification. UV absorbance
measurements were obtained with a Beckman DU®-65 spectrophotometer. 1H NMR spectra
were recorded on a Varian Mercury 300, Bruker Advance 400, Bruker Advance 401, or Varian
INOVA 500 NMR spectrometers. 195Pt NMR spectra were recorded on Varian INOVA 501
NMR spectrometer equipped with a tunable broad-band probe. The chemical shifts were
reported as δ (ppm) values calibrated to solvent peaks for 1H NMR spectra, whereas cisplatin
(-2088 ppm in DMF) was used as an external reference for the 195Pt NMR spectra. The splitting
of proton resonances in the reported 1H NMR spectra are defined as s = singlet, d = doublet, t
= triplet, q = quartet, and m = multiplet. Quantification of radioactivity was performed on a
Beckman LS 1801 Liquid Scintillation Counter or on a Molecular Dynamic Storm 840
PhosphorImager equipped with Molecular Dynamic ImageQuant software. High-resolution
mass spectral analyses were carried out by the MIT Department of Chemistry Instrumentation
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Facility (DCIF). Elemental analyses were performed by Quantitative Technologies Inc. (QTI),
Whitehouse, NJ.
2.2 Synthesis of Pt compounds
(6-Hydroxyhexyl)-carbamic acid 2-(diphenylphosphinic-{6-[7α-estra-1,3,5,(10)
triene-3,17β-bis-2-tetrahydropyranyl]-hexyl}-amino)-ethyl ester (2)—To a solution
of 1 (460 mg, 0.485 mmol) in 30 mL of DMF, was added 6-aminohexanol (74 mg, 0.631 mmol)
at room temperature. The reaction mixture was stirred for 12 h. After removing solvent under
reduced pressure, the residue was re-dissolved in 50 mL of CH2Cl2 and partitioned between
Na2CO3 saturated aqueous solution (50 mL) and CH2Cl2. The organic phase was dried over
Na2SO4. The product was purified by column chromatography on silica gel (EtOAc/25%
CH2Cl2 → CH2Cl2/10% MeOH) to yield 2 as white solid (400 mg, 89 %). 1H NMR (CDCl3)
δ 0.79, 0.81 (2s, 3H), 0.9–2.1 (42 H), 2.28 (m, 2H), 2.69 (2d, 1H), 2.85 (m, 1H), 2.95 (q, 2 H),
3.13 (q, 2H), 3.25 (m, 2H), 3.49 (m, 1H), 3.56–3.66 (m, 3H), 3.75 (t, 1H), 3.92 (m, 2H), 4.01
(t, 2H), 4.66 (m, 1H), 4.97 (t, 1H), 5.38 (2t, 1H), 6.76 (d, 1H), 6.84 (d, 1H), 7.18 (t, 1H), 7.40–
7.5 (m, 6 H), 7.81 (m, 4H).
[6-(2-Amino-ethylamino)-hexyl]-carbamic acid 2-({6-[7α-estra-1,3,5,(10)
triene-3,17β-bis-2-tetrahydropyranyl]-hexyl}-diphenylphosphinic-amino)-ethyl
ester (3)—To a solution of 2 (400 mg, 0.43 mmol) in 10 mL of pyridine, was added
methanesulfonyl chloride (67 μL, 0.86 mmol) via micro syringe at room temperature. The
resulting mixture was stirred at room temperature for 30 minutes, after which 60 μL of water
was added, followed by ethylendiamine (10 mL). After stirring at room temperature for 20 h,
the volatile components of the reaction mixture were removed under the reduced pressure. The
residue was dissolved in 10 mL of CH2Cl2, and partitioned between Na2CO3 saturated water
and CH2Cl2. The organic phase was then dried over Na2SO4 and evaporated under reduced
pressure. The residue was re-dissolved in 10 mL of acetonitrile and insoluble white
precipitation was removed by filtration. The crude product in acetonitrile was purified by
column chromatography on alumina gel (CH2Cl2/5% MeOH → CH2Cl2/5% MeOH/0.5%
NH4OH) to yield 3 (250 mg, 63 %). 1H NMR (CDCl3) δ 0.79, 0.81 (2s, 3H), 0.9–2.1 (42 H),
2.28 (m, 2H), 2.65–2.75 (m, 2H), 2.85- 2.99 (m, 6H), 3.10 (t, 2H), 3.25 (m, 2H), 3.48 (m, 1H),
3.59 (m, 1H), 3.73 (t, 1H), 3.91(m, 2H), 4.10 (m, 2H), 4.66 (m, 1H), 5.38 (2t, 1H), 6.75 (d,
1H), 6.84 (d, 1H), 7.18 (t, 1H), 7.40–7.45 (m, 6H), 7.78 (m, 4H)
[6-(2-Amino-ethylamino)-hexyl]-carbamic acid 2-[6-(7α-estra-1,3,5,(10)-triene)-
hexylamino]-ethyl ester (4) (Est-en)—To a stirred solution of 3 (110 mg, 0.11 mmol) in
10 mL of methanol at room temperature, was added concentrated HCl (0.5 mL) drop wise. The
resulting solution was stirred for 3–6 h with TLC monitoring. Solid Na2CO3 was added to the
reaction mixture until all of HCl was neutralized. The excess Na2CO3 solid was removed by
filtration and the solvent was evaporated under reduced pressure. The resulting products were
re-dissolved in 20 mL of ethanol and insoluble material removed by filtration. Following
removal of solvent the removed product was washed with CH2Cl2 (10 mL) several times to
yield 4 (Est-en) (70 mg, 0.11 mmol, quantitative). 1H NMR (CD3OD) δ 0.73 (s, 3H), 0.92–
1.77 (27 H), 1.87 (d, 1H), 1.98 (m, 1H), 2.25 (m, 2H), 2.64 (d, 1H), 2.77 (dd, 1H), 2.96 (t, 2H),
3.02–3.10 (m, 4H), 3.21 (m, 2H), 3.61 (t, 1H), 4.22 (m, 2H), 6.48 (d, 1H), 6.92 (dd, 1H), 7.03
(d, 1H). HRMS (ESI) calculated for [M+H] 601.4687, found 601.4684.
[6-(2-Amino-ethylamino)-hexyl]-carbamic acid 2-[6-(7α-estra-1,3,5,(10)-triene)-
hexylamino]-ethyl ester platinum(II) dichloride ((Est-en)PtCl2)—To a stirred
solution of 4 (Est-en) (85 mg, 0.141 mmol) in 5 mL of MeOH/H2O (3:2 v/v), was added a
solution of K2PtCl4 (70 mg, 0.17 mmol) in 4 mL of MeOH/H2O (1:1 v/v). The resulting mixture
was stirred for 24 h at room temperature in the dark. A 10% KCl aqueous solution was added
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and the reaction was stirred for additional 4 h in the dark. After letting the white precipitate
settle to the bottom of the flask on ice for an hour, the supernatant was decanted. Any remaining
suspended material was removed by centrifugation and combined with the original precipitate.
The off-white solid was washed 4X with 1 ml of water by resuspension and centrifugation.
Finally, the cream solid was dried under vacuum for 12 h to yield (Est-en)PtCl2 (83 mg, 0.096
mmol, 68 %). Note: the reaction yield varied (25–70 %) depending on the scale of the reaction.
The larger the reaction scale, the higher reaction yield. 1H NMR (DMF-d7) δ 0.79 (s, 3H), 0.9–
1.80 (26 H), 1.85–2.0 (m, 3H), 2.25 (m, 2H), 2.60 (m, 2H), 3.05 (m, 3H), 3.75 (m, 1H), 4.02
(m, 2H), 4.58 (d, 1H), 5.22 (br, 2H), 6.10 (br, 1H), 6.49–6.70 (m, 2H), 7.00 (t, 1H), 7.13 (d,
1H), 9.20 (br, 1H). 195Pt NMR (DMF-d7) δ -2341. HRMS (ESI) calculated for [M+H]
867.3705, found 867.3681. Elemental analysis, calculated for C35H60Cl2N4O4Pt•2H2O: C
46.56; H 7.14; N 6.21. Found: C 46.89; H 7.01; N 6.14.
N-(6-Hydroxylhexyl)benzamide (5)—A mixture of 6-aminohexanol (500 mg, 4.27 mmol)
and benzoic anhydride (1 g, 4.42 mmol) was dissolved in 50 mL of DMF and stirred for 12 h
at room temperature. After removing DMF, the products were partitioned between CH2Cl2
and aqueous Na2CO3 (sat.). The organic phase was dried over Na2SO4. The product was
isolated by column chromatography on silica gel (EtOAc/33% hexanes) to yield 5 as white
solid (870 mg, 92%). 1H NMR (DMSO-d6) δ 1.28–1.54 (m, 8 H, - CH2-), 3H), 3.25 (q, 2H, -
CH2-NHC(O)-), 3.38 (q, 2H, -CH2-OH), 4.36 (t, 1H, -OH), 7.41–7.51 (m, 3H, meta & para
C6H5-), 7.82 (m, 2H, ortho C6H5-), 8.43 (t, 1H, -NHC(O)-).
N-[6-(2-Amino-ethylamino)-hexyl]-benzamide (6) (Bz-en)—To a stirred solution of
5 (2.5 g, 0.01 mol) in 50 mL of pyridine, was added methanesulfonyl chloride (1.7 mL, 0.02
mol) at room temperature. The resulting solution was stirred for 30 minutes, after which 2 mL
of water was added. Excess ethylenediamine (10 mL) was then added to the reaction mixture
which was further stirred for an additional 20 h. The volatile components of the reaction mixture
were removed under the reduced pressure. The remaining residue was partitioned between
aqueous Na2CO3 (sat.) and CH2Cl2. The organic phases were dried over Na2SO4. The product
was isolated by column chromatography (alumina, 90%CH2Cl2/10%MeOH/1%NH4OH) to
yield 6 (Bz-en) as hygroscopic white solid (1.8 g, 68 %). 1H NMR (D2O) δ 1.22–1.30 (m, 4H,
-CH2-), 1.34- 1.39 (m, 2H, -CH2-), 1.47–1.53 (m, 2H, -CH2-), 2.41 (t, 2H, -CH2- next to -
NH(2)), 2.49 (t, 2H, -CH2- next to -NH(2)), 2.60 (t, 2H, -CH2- next to -NH(2)), 3.26 (t, 2H, -
CH2-NHC(O)), 7.42 (t, 2H, meta C6H5-), 7.50 (t, 1H, para C6H5-), 7.65 (d, 2H, ortho
C6H5-). HRMS (ESI) calculated for [M+H] 264.2070, found 264.2069.
N-[6-(2-Amino-ethylamino)-hexyl]-benzamide platinum(II) dichloride ((Bz-en)
PtCl2)—To a stirred solution of 6 (Bz-en) (300 mg, 1.14 mmol) in water (3 mL) was added a
solution of K2PtCl4 (473 mg, 1.14 mmol in 2 mL of H2O). The resulting soultion was stirred
for 25 h in dark. An aqueous solution of 5 % KCl (10 mL) was added to the reaction mixture
which was stirred an additional 3 h. Suspended solids were then collected by centrifugation,
triturated with water four times and finally the solid was dried under vacuum for 12 h to yield
(Bz-en)PtCl2 as a fine tan power (520 mg, 86 %). 1H NMR (DMF-d7) δ 1.31- 1.40 (m, 4H, -
CH2-), 1.59- 1.65 (m, 3H, -CH2-), 1.91 (m, 1H, -CH2-), 2.55–2.82 (m, 4H, -CH2- next to -
NH(2)), 2.94 (m, 1H, -CH2- next to -NH(2)), 3.08 (m, 1H, -CH2- next to -NH(2)), 3.38 (t, 2H,
-CH2-NHC(O)), 5.20 (s (br), 2H, -NH2), 6.05 (s (br), 1H, -NH-), 7.46–7.50 (m, 2H, para
C6H5-), 7.95–7.98 (m, 2H, ortho C6H5-), 8.47 (7.50 (t, 1H, para C6H5-), 7.65 (d, 2H, ortho
C6H5-), 8.43 (t, 1H, -NHC(O)-). ). 195Pt NMR (DMF-d7) δ -2343. Elemental analysis,
calculated for C15H25Cl2N3OPt: C 34.03; H 4.76; N 7.94. Found: C 34.32; H 4.74; N 7.85.
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2.3 Reaction of Pt compounds with DNA
Platinated compounds (4 nmol) were allowed to react with a 5′[32P]-labeled self-
complementary oligonucleotide 5′-d(ATTATTGGCCAATAAT) (0.8 nmol) dissolved in 40
μL phosphate buffer (50 mM, pH=7.4) for 12 h at 37°C. The DNA was recovered by ethanol
precipitation and analyzed by separation on a denaturing 20% polyacrylamide gel.
Quantification of radioactivity was performed on a Molecular Dynamic Storm 840
PhosphorImager equipped with Molecular Dynamic ImageQuant software. The level of
modification was estimated by the ratio of the amount of unmodified DNA to the amount to
DNA with lower mobility in each lane on the gel. Analysis of DNA modification by (Bz-en)
PtCl2 and (Est-en)PtCl2 was performed twice, whereas the analysis of DNAs treated DMSO
or cisplatin was performed once.
2.4 Affinity of (Est-en)PtCl2 for the estrogen receptor
The relative affinity of (Est-en)PtCl2 for the estrogen receptor was determined by a competitive
binding assay using the human ER ligand binding domain (hER-LBD) (Invitrogen, Carlsbad,
CA). [3H]-17β-Estradiol (50 nM) was combined with unlabeled competitors (0.1 nM to 100
μM) and 2.7 nM hER-LBD in 150 μL of 10 mM Tris-Cl pH 7.5, 10% glycerol, 2 mM
dithiothreitol, 1 ml/ml BSA. The solution was incubated at 4°C for 12 h. Bound and free ligands
were separated by absorbtion of the hER-LBD to hydroxyapatite (HAP). After incubation, 100
μL of a 50% slurry of HAP in binding solution was added and allowed to absorb the hER-LBD
for 15 min at 4°C. The HAP was washed three times with binding buffer. HAP pellets were
resuspended in 2 ml ethanol, scintillation fluid added and radioactivity measured. The relative
binding affinity (RBA) was calculated as the percent ratio of 17β-estradiol divided by the test
compound required to reduce bound radioactivity by 50%. The experiment was performed in
duplicate.
2.5 Affinity of (Est-en)PtCl2-DNA adducts for hER-LBD
The [32P]-labeled self-complementary 16-mer deoxyoligonucleotide was allowed to react with
platinum compounds as described above. Unreacted (Est-en)PtCl2 was removed using a Micro
Bio-Spin 6 column (BioRad, Hercules, CA). DNA containing adducts formed by (Est-en)
PtCl2 or unreacted DNA (7.6 pmol) was combined with hER-LBD (3.9 pmol) in 10% glycerol,
2 mM DTT and 10 mM Tris pH 7.5 (20 μL final volume). 17β-Estradiol (25 fmol – 25 pmol)
was added as competitor to the solutions where indicated. After 1 h at room temperature
complexes were separated on a 5% polyacrylamide gel containing 0.5xTBE and run at 4°C.
The data shown represent the results of three independent experiments.
2.6 Cell culture
The cell lines used in this study were obtained from the American Type Culture Collection
(ATCC, Rockville, MD). HeLa, MDA-MB231 and MCF-7 cell lines were maintained in
Minimal Essential Media (MEM) (Invitrogen, Carlsbad, CA) supplemented with 10% fetal
bovine serum (FBS) (Hyclone, Logan, UT), 2 mM glutamine, 1 mM sodium pyruvate, and 0.1
mM nonessential amino acids. The GM04312 cell line (i.e., Xeroderma Pigmentosum
Complementation Group A; XPA) was maintained in MEM supplemented with 10% FBS and
2 mM glutamine. CAOV-3 cells were maintained in Dulbecco’s Modified Eagle Medium
(DMEM) (Invitrogen, Carlsbad, CA) supplemented with 10% FBS. Cells were grown in a
humidified 5% CO2/air atmosphere at 37 °C.
2.7 Growth inhibition and clonal survival assays
For the growth inhibition assay cells were seeded at 7 × 104 cells/well in 6-well plates and
allowed to adhere to the surface for 24 h. Cells were then exposed to the platinated test
compounds dissolved in DMSO, as well as DMSO alone in growth medium with a reduced
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serum content (0.5% FBS) for 48 h. At the end of the incubation, cells were trypsinized and
cell numbers determined using a Coulter Counter. The percent growth inhibition is the ratio of
cell number in compound-treated and DMSO-treated wells multiplied by 100. The results
represent the averages of three independent experiments each of which was performed in
duplicate or triplicate for each concentration of test compound. The LD50 values were estimated
from the growth inhibition curves.
Clonal survival assays with HeLa or XPA (GM04312) cells were performed by seeding 6-well
dishes at 1000 cells/well. Cells were allowed to adhere to the surface for 24 h. Cells were then
exposed for 24 h to test compounds in growth media with a reduced serum content (0.5% FBS).
Fresh growth media (containing 10% FBS) was then added cells were grown for 5–7 days.
Colonies were fixed with acetic acid/methanol, stained with crystal violet and counted. The
assay was repeated twice with triplicates for each concentration of test compound.
3. Results
A number of platinum complexes linked to steroids have been designed to take advantage of
steroid transport mechanisms to increase the intracellular accumulation of drug [14,15,16,17,
18,19]. In addition to affecting toxicant transport, our study was aimed at the construction of
a molecule that would disrupt the processes of DNA repair and transcription. We chose the
estrogen receptor as the cancer cell-expressed target for several reasons. The ER is expressed
in most ovarian cancers which, although initially responsive to platinum chemotherapeutics,
frequently develop resistance through increased DNA repair abilities [9]. Moreover, the ER,
when up regulated, drives genes for growth of cancer cells. Our goal in this work was to
determine, in part, if our repair-blocking or transcriptional disruption strategies (Fig. 1) might
be able to enhance the selective toxicity of platinating agents against cancer cells expressing
the ER. For this study, we used a linker we had shown in earlier work permits the juxtaposition
of the ER with DNA damage sites in the genome; this linker is attached to the steroid residue
at the 7α position [13].
The preparation of the estradiol-platinum compound (Est-en)PtCl2 (Scheme 1) was based in
part on previously published methods. The key precursor, the estradiol-linked carbonate (1)
was prepared by methods described in an earlier publication by our research group [13].
Carbonate (1) was then allowed to react with aminohexanol to form the carbamate (2). The
terminal alcohol group of (2) was activated and coupled to ethylenediamine to yield, after acid
deprotection, (4) Est-en. The platinum complex was prepared by addition of an aqueous
solution of K2PtCl4 to a solution of the Est-en ligand and the product isolated directly from
the reaction mixture. Using similar methods, we synthesized a N-(6-hexyl)benzamide
derivative of ethylenediamminePt(II), (Bz-en)PtCl2 (Scheme 2). This molecule was designed
as a control to investigate that role played by the steroid moiety in the estradiol-linked Pt
compound (Est-en)PtCl2. The coordination of the Pt to the diamine in each complex was
confirmed by NMR. The 195Pt chemical shift values of (Est-en)PtCl2 (-2341) and (Bz-en)
PtCl2 (-2343) are characteristic of platinum(II) complexes with a diamine accompanied by two
chloride atoms [20,21].
We used gel electrophoresis to assess the ability of the platinum compounds to react with DNA
and form covalent adducts. Upon overnight incubation with a radio-labeled self complementary
16-mer, 5′[32P]-d(AATATTGGCCAATATT), containing the preferred platinum binding site
d(GpG) [22] (Figure 2 inset, indicated by arrows), cisplatin as well as the (Est-en)PtCl2 and
(Bz-en)PtCl2 compounds displayed their ability to modify DNA by the appearance of slower
migrating bands (Figure 2; bands in boxes). While only a trace amount of DNA remained
unmodified by cisplatin, greater amounts of unmodified DNA are present after reaction with
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the (Est-en)PtCl2 and (Bz-en)PtCl2 compounds indicating the order of reactivity as cisplatin
> (Bz-en)PtCl2 > (Est-en)PtCl2.
We next examined the ability of free (Est-en)PtCl2 to bind to the ER using a competitive ligand
binding assay. In the presence of cell extracts containing the human ER ligand binding domain
(hER-LBD) and [3H]-17β estradiol, increasing concentrations of (Est-en)PtCl2 resulted in
deceased radioligand associated with the ER (Figure 3a). In comparison to estradiol, (Est-en)
PtCl2 had a relative binding affinity (RBA) of 28% (i.e., the RBA of 17β-estradiol = 100).
We next used an electrophoretic mobility shift assay (EMSA) to determine whether the ER
can bind to the DNA adducts of (Est-en)PtCl2. The self-complementary 16-mer was allowed
to react with (Est-en)PtCl2 as described above and the product was incubated with purified
hER-LBD at room temperature for 45 min. Analysis on a 5% non-denaturing polyacrylamide
gel revealed that DNA containing (Est-en)PtCl2 adducts produced slowly migrating bands in
the presence of the ER-LBD (Figure 3b, lane 3). The presence of two complexes with slightly
different mobilities likely results from different orientations of Pt bound in the oligonucleotide
DNA. Similar observations of isomeric DNA binding with asymmetric platinum complexes
have been previously reported [23]. It is also possible that the two bands represent complexes
formed by the ER binding to inter- and intra-strand crosslinked DNA. The slowly migrating
complexes disappeared when increasing amounts of 17β-estradiol were added to the reactions
(lanes 4–8) (Figure 3b). The ability of the natural ligand to dissociate the ER from modified
DNA suggests that complex formation results from a specific association between (Est-en)
PtCl2-DNA adducts and the ER.
The cytotoxic effects of (Est-en)PtCl2 and (Bz-en)PtCl2 were compared in the human ovarian
cancer cell line CAOV3, which expresses the ERα [24]. Toxicity was evaluated by comparing
the number of cells in wells after 48 h treatment with either compound to the number of cells
in wells treated with vehicle only. The results in Figure 4A show that (Est-en)PtCl2, with an
LD50 of 25 μM, is much more potently cytotoxic than (Bz-en)PtCl2 against CAOV3 cells.
This enhanced toxicity is possibly owed to (i) diminished repair, (ii) enhanced uptake or (iii)
disrupted transcription, as indicated in Figure 1. It is noteworthy that the high differential
toxicity of (Est-en)PtCl2 over (Bz-en)PtCl2 is achieved despite its lower inherent ability to
damage DNA (Fig. 2).
We next examined whether the ability to perform nucleotide excision repair (NER) was capable
of modulating the cytotoxic effects of (Est-en)PtCl2. The NER pathway is one of the major
cellular defenses against DNA damage caused by cisplatin [6]. The cytotoxicity of (Est-en)
PtCl2 towards an XPA (NER-negative) cell line was compared with its cytotoxic effects
towards the NER repair proficient HeLa cell line. Using a clonal survival assay, we found
repair-deficient XPA cells suffered greater toxicity from (Est-en)PtCl2 than did repair-
proficient HeLa cells (Figure 4B). This result supports the notion that (Est-en)PtCl2 DNA
lesions are substrates for NER and helps to identify DNA as an important cellular target of this
drug candidate.
Finally, we tested the role of the ER in mediating the cytotoxicity of (Est-en)PtCl2 in vitro by
determining its antiproliferative effects on the breast cancer cell lines MDA-MB231 (ER-) and
MCF-7 (ER+). Figure 4C shows that at concentrations < 20 μM (Est-en)PtCl2 inhibited growth
of the MCF-7 cell line to a greater extent than it did the MDA-MB231 cell line. These results
along with those shown in Figure 4A indicate that both the presence of the estradiol moiety in
(Est-en)PtCl2 and expression of the ER in target cells lead in enhanced toxicity.
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4. Discussion
Acquired or intrinsic resistance limits the clinical use of platinum-based therapeutics to a
relatively narrow range of tumor types. One strategy described in the literature to overcome
resistance mechanisms and expand the range of treatable tumors has been to link platinum (II)-
coordination complexes to amino acids, steroids, DNA intercalators or other ligands that alter
transport or chemical reaction properties [21,25,26]. These manipulations have been intended
to achieve selective transport and accumulation of platinum compounds in the DNA of tumor
cells. The notion that estradiol-linked platinum complexes might be selectively enriched in ER
+ tumor cells led to the design and evaluation of platinum compounds with affinity for the ER
[19,18,15,27].
We were not solely interested, however, in improving the transport properties of the platinum-
warhead complex into cells, although that mechanism would certainly be beneficial. The key
feature of the designed genotoxicant, (Est-en)PtCl2, is the linker that adjoins the warhead and
ligand portions of the molecule. This linker was designed to permit the steroid portion to
interact with the ER even after the platinum warhead has reacted with DNA (Figure 3). Thus
the molecule was designed to combine some features of molecules designed by others that
provide enhanced bioavailability, and new features that incorporate different mechanisms of
toxicity, namely DNA repair inhibition and quenching of transcriptional responses.
At present, three non-mutually exclusive models are proposed to explain the enhanced toxicity
of the platinum-steroid conjugate: (i) preferential uptake and sequestration of (Est-en)PtCl2
into ER positive cells, (ii) shielding of DNA adducts of (Est-en)PtCl2 from DNA repair
enzymes by the ER, and (iii) hijacking of the growth promoting transcriptional activity of the
ER by (Est-en)PtCl2-DNA adducts.
Regardless of mechanism, the impact of the steroid ligand as a structural feature to target the
toxicity of (Est-en)PtCl2 is very significant, as indicated in Figure 4A. This compound is less
reactive with DNA in vitro than the ligand-less control, (Bz-en)PtCl2, yet it shows strikingly
enhanced toxicity against an ER positive ovarian cancer line. Likewise, increased toxicity of
(Est-en)PtCl2 towards the ER+ breast cancer cell line MCF-7 (compared to ER- MDA-MB231;
Figure 4C) suggests that one aspect of its mechanism of action involves the ability to bind to
the ER. The fact that we observe no differences at >20 uM could represent a threshold at which
the number of DNA adducts overwhelms the repair capacity in either cell line – in which case
diminished repair in the ER+ line would not lead to greater toxicity. While detailed mechanistic
studies have not been done on (Est-en)PtCl2, the data in Figure 4B provide insight into the
cellular target responsible for toxicity. The greater toxicity of (Est-en)PtCl2 against DNA repair
deficient cells than against wild type cells indicates that the compound is indeed reaching its
intended target, DNA. Future studies will investigate the relative contributions of the
hypothetical mechanisms of DNA repair shielding and steroid receptor transcriptional
hijacking along with cellular uptake to the overall toxicity of (Est-en)PtCl2 in steroid receptor
positive cancer cells.
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DTT dithiothreitol
ER estrogen receptor
ESI electron spray ionization
FBS fetal bovine serum
HRMS high resolution mass spectrometry
LBD ligand binding domain
NER nucleotide excision repair
RBA relative binding affinity
TBE tris-borate-EDTA
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Figure 1.
Structures and proposed mechanisms of toxicity of Pt(II) complexes. A. The (Bz-en)PtCl2
compound, which does not bind to the ER, forms DNA adducts that can be repaired and does
not antagonize ER function. B. The (Est-en)PtCl2 compound contains a ligand that enables the
ER to bind to DNA adducts and prevent repair. Association of the ER with adducts also disrupts
transcription of ER-regulated genes.
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Figure 2.
Covalent modification of a 16-mer deoxyoligonucleotide by platinum compounds: (Right
Panel) Separation of modified and unmodified DNA by gel electrophoresis; (Left Panel)
Percentage of DNA modified by each compound as determined by PhosphorImager analysis.
(Representative of two independent experiments.)
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Figure 3.
Ability of (Est-en)PtCl2 and (Est-en)PtCl2-DNA adducts to bind to the hER-LBD: A.
Competitive binding of 17β-estradiol (-•-) or (Est-en)PtCl2 (-■-) with [3H]-17β-estradiol for
the hER-LBD (Points, mean ± S.D.). B. Gel mobility shift assay: Lane 1, (Est-en)PtCl2-
modified DNA; Lane 2, unmodified DNA + hER-LBD; Lane 3, (Est-en)PtCl2-modified DNA
+ hER-LBD; Lanes 4–8 (Est-en)PtCl2-modified DNA + hER-LBD + 17β-estradiol (0.13 – 13
uM) (Representative of three independent experiments).
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Figure 4.
Effect of platinum compounds on cell survival: A. Cytotoxicity of (Est-en)PtCl2 (-▲-) and
(Bz-en)PtCl2 (-■-) towards CAOV-3 cells as measured by growthinhibition. B. Cytotoxicity
of (Est-en)PtCl2 towards NER-deficient XPA cells (-•-) and NER-proficient HeLa cells (-
◆-) as measured by clonal survival. C. Cytoxicity of (Est-en)PtCl2 towards ER-, MDA-
MB231 (-■-) and ER+ MCF-7 (-▲-) breast cancer cells as measured by growth inhibition.
Points, mean of two independent experiments performed in triplicate ± S.D.
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Scheme 1.
Strategy for the preparation of (Est-en)PtCl2
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Scheme 2.
Strategy for the preparation of (Bz-en)PtCl2
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